Perloc

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perloc

Property Description
Active ingredient Pantoprazole (Pantoprazole sodium)
Form Delayed-release, enteric-coated tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic substituted benzimidazole

What is Perloc and What Type of Drug is it?

Perloc is a medication whose active component is pantoprazole, a synthetic compound classified as a potent Proton Pump Inhibitor (PPI). This drug is specifically designed to manage conditions arising from uncontrolled acid production within the stomach.


Perloc belongs to the group of anti-secretory agents, chemically defined as a substituted benzimidazole. The function of this pharmacological class is to exert powerful, sustained control over acid output. As a single-active-ingredient preparation, it is distinct from simple antacids as it targets the fundamental process of acid creation rather than merely neutralizing acid that has already been released. Pantoprazole is a PPI that achieves anti-secretory results by reducing the amount of acid the stomach makes. Perloc, typically available as a prescription-only medication, represents a widely utilized and chemically stable form of pantoprazole.

Pantoprazole's General Purpose and Anti-Secretory Action

The general purpose of Perloc is to significantly and reliably decrease gastric acid secretion by interfering with the stomach's acid-producing mechanism. This anti-secretory action helps to create a less acidic environment, which is the foundational therapeutic benefit.


The core action of pantoprazole involves the irreversible inhibition of the proton pumps located in the parietal cells of the stomach. By disabling this H^+K^+-ATPase enzyme system, the drug effectively suppresses the final step in the acid production process. This sustained acid reduction helps to manage the overall acidic load and promotes comfort and tissue maintenance where acidity has been an issue. Pantoprazole's mechanism is characterized by high specificity toward the proton pump, directly inhibiting the final stage of acid production.

Forms, Delivery Method, and Formulation

Perloc is most commonly manufactured as an enteric-coated, delayed-release tablet intended for the oral route of administration, positioning it as a convenient, non-invasive treatment option.


The specialized enteric coating protects the active ingredient, pantoprazole, from the destructive effects of the highly acidic environment it encounters upon entering the stomach. Because the stability of this compound is pH-dependent, the coating ensures that the drug remains intact until it reaches the less acidic environment of the intestine, allowing for optimal absorption and delivery to the targets. Alternative formulations, such as delayed-release granules or powder for intravenous (IV) formulation, are also options for administration.

Regulatory References

  1. National Institutes of Health
  2. DrugBank
  3. gastric acid secretion

What side effects are possible with Perloc?

Possible Side Effects and Safety Information

The official safety profile for Perloc (pantoprazole) documents adverse reactions according to frequency and affected system, as classified by regulatory authorities.

Documented Adverse Reactions by Frequency

Adverse reactions are formally categorized based on clinical trial and post-marketing data:

Classification Examples of Documented Reactions
Common (ge 1/100 to <1/10) Headache, Diarrhea, Nausea, Vomiting, Dizziness, Abdominal pain, Benign Fundic Gland Polyps
Uncommon (ge 1/1,000 to <1/100) Sleep disorders, Fatigue, Rash, Pruritus, Increased liver enzymes, Bone Fracture
Rare (ge 1/10,000 to <1/1,000) Hypersensitivity reactions, Anaphylaxis, Depression, Blood changes (e.g., Agranulocytosis)

Common effects primarily involve the Gastrointestinal and Nervous Systems. The risk of Bone Fracture of the hip, wrist, or spine is documented as uncommon, associated with long-term, high-dose therapy.

Serious and Clinically Important Safety Risks

Regulatory documents highlight several serious adverse reactions. These include severe allergic reactions such as Anaphylactic shock and Severe Cutaneous Adverse Reactions (SCAR). Post-marketing surveillance has identified the risk of Acute Interstitial Nephritis (AIN), a kidney inflammation that can occur at any time during treatment. Additionally, Hypomagnesaemia (low blood magnesium), potentially leading to serious complications like arrhythmia or seizures, is reported rarely with prolonged treatment, typically after one year or more.

Population and Duration-Related Safety

Safety notes address risks tied to the duration of exposure. Long-term use is associated with the increased risk of Fundic Gland Polyps, Hypomagnesaemia, and Vitamin B-12 deficiency. The medication is generally contraindicated in patients with a known hypersensitivity to the active substance. Furthermore, symptomatic improvement does not rule out gastric malignancy, as the drug may mask symptoms and delay diagnosis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents stipulate that you must seek immediate medical attention for any suspected overdosage of Perloc. This instruction is mandatory due to the inherent risks associated with medication overexposure.


Documented Overdose Profile

Experience with subjects who have taken excessively high doses of pantoprazole, the active ingredient in Perloc, is limited. The official prescribing information does not document specific unique symptoms or signs that are exclusively attributed to a single, acute overdosage. In clinical studies, even high daily doses (up to 240 mg) were generally reported as well-tolerated, though these scenarios require medical supervision.


Required Emergency Action and Management

In the event of a suspected overdose, there is no specific antidote known for pantoprazole. Because of this, the required management is strictly limited to symptomatic and supportive treatment. A key procedural note is that the drug is not effectively removed by hemodialysis, owing to its high binding to plasma proteins.

This regulatory profile emphasizes that although specific acute toxic effects are not well-documented, professional assessment is required immediately to manage any resulting clinical manifestations effectively with supportive care.

Therapeutic Uses of Perloc

What Perloc Treats: Main Uses and Benefits

Perloc is generally applied in therapeutic domains where supportive management of symptoms related to irritative or inflammatory states is appropriate, particularly in the management of conditions related to gastric acid.


The medication is commonly used across conditions presenting with episodic or fluctuating manifestations. It is relevant for easing symptoms related to physical discomfort associated with erosive esophagitis (EE), Gastroesophageal Reflux Disease (GERD), and conditions characterized by periods of heightened symptoms, such as pathological hypersecretory states like Zollinger-Ellison syndrome. It may assist in addressing symptoms linked to organ-specific functional stress, such as peptic ulcers in the stomach or duodenum.

“Supports the patient during difficult episodes by easing distress and contributes to the body's maintenance of functional stability.”

In these clinical scenarios, Perloc may assist with symptomatic relief for the pronounced manifestations of GERD, including persistent heartburn and regurgitation. By contributing to easing the overall symptom load, it supports patients during episodes of heightened discomfort that create noticeable physiological strain.


Quick Fact: Supportive Management for Persistent Heartburn

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Population Eligibility for Perloc (Pantoprazole)

Eligibility for Perloc is defined by regulatory bodies based on age, existing medical conditions, and sensitivity history.

Classification Population Status Defined by Regulators
Contraindicated Hypersensitivity Must not use if allergic to pantoprazole or substituted benzimidazoles.
Specific HIV Medications Must not use concurrently with certain pH-dependent HIV protease inhibitors (e.g., atazanavir, rilpivirine).
Age-Related Rule Children Under 5 Safety and effectiveness not established for general use.
Children 5 to 17 Approved for short-term treatment of conditions like erosive esophagitis (EE).
Condition-Based Severe Hepatic Impairment Use is restricted; a maximum daily dose must be observed.
Renal Impairment Standard eligibility; no dose adjustment is necessary.
Physiological State Pregnancy/Lactation Use is conditional/restricted and advised only when the potential benefit outweighs the risk, as the drug is excreted into human milk.

Adults (18 and older) are generally eligible for all labeled indications. The label mandates that gastric malignancy must be excluded before starting therapy in adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Perloc (a Proton Pump Inhibitor) has documented interactions primarily stemming from its ability to increase the pH level within the stomach, which is essential for the systemic absorption of certain co-administered medicines.

Products to Avoid and High-Risk Combinations

  • Antiretroviral Medicines: Concomitant use with specific antiretroviral agents, including atazanavir, nelfinavir, and rilpivirine-containing products, is discouraged or restricted in regulatory labeling. The co-administration is associated with a risk of reduced drug exposure for the antiretrovirals, which can lead to a loss of therapeutic effect and the potential for drug resistance.
  • Drugs Requiring Acidic pH: Medicines whose bioavailability is dependent on an acidic gastric pH—such as iron salts, erlotinib, dasatinib, nilotinib, and certain antifungal agents like ketoconazole and itraconazole—may have their absorption substantially decreased when taken with Perloc.

Combinations Requiring Close Monitoring

  • Coumarin Anticoagulants (e.g., Warfarin): Official labeling reports that co-administration may cause an increase in the International Normalized Ratio (INR) and Prothrombin Time (PT). Close monitoring of these coagulation parameters is required upon initiation, dosage change, or discontinuation of Perloc.
  • Methotrexate: The co-administration of Perloc with methotrexate has been documented to result in increased and prolonged serum concentrations of methotrexate and its metabolite, necessitating careful use and observation.

Interference with Diagnostic Tests

  • Perloc may produce false-positive results in urine screening tests for Tetrahydrocannabinol ( THC). Confirmation using an alternative, specific method is necessary for such results.

Mechanism of Action

️ Biological Target: Irreversible Proton Pump Inhibition

Perloc is a substituted benzimidazole that acts as a prodrug, accumulating selectively within the acidic environment of the secretory canaliculi of the gastric parietal cells. The active metabolite then selectively and covalently binds to the H^+/ K^+- ATPase enzyme, widely known as the gastric proton pump. This binding action irreversibly inactivates the enzyme, thus engaging mechanisms that modulate the final step in hydrochloric acid secretion.


Pathway Modulation: Sustained Acid Secretion Reduction

By irreversibly inhibiting the H^+/ K^+- ATPase across the parietal cell surface, Perloc modifies the activity of the enzyme responsible for translocating hydrogen ions into the stomach lumen. This mechanistic cascade results in a profound and long-lasting reduction in both basal (non-stimulated) and stimulated gastric acid output. This system-level physiological consequence represents the targeted pathway adjustment.

Dosage and Administration Information

How to Use Perloc

Perloc (pantoprazole) is administered via the oral route (delayed-release tablets or granules) or the intravenous (IV) route for patients unable to take oral medication. The administration instructions are precise to ensure the delayed-release formulation is utilized correctly, protecting the active ingredient until it reaches the intestine.


Official Administration Guidelines

Property Instruction
Route of Administration Oral (Tablet, Granules) or Intravenous (IV) Injection/Infusion.
Dosing Schedule Standard adult dose is typically 40 mg once daily. For pathological hypersecretory conditions, the dose may be 80 mg twice daily or adjusted upward, with documented daily doses up to 240 mg.
Timing in Relation to Meals Delayed-release tablets may be taken with or without food. Delayed-release granules must be administered approximately 30 minutes prior to a meal.
Special Handling Oral tablets and granules must be swallowed whole; they must not be split, crushed, or chewed. IV administration requires the powder to be reconstituted and diluted, and the intravenous line should be flushed before and after administration.
Duration Short-term oral treatment is generally up to 8 weeks. IV therapy is limited to 7 to 10 days, followed by transition to oral therapy when feasible.

Population-Specific Use

Severe Hepatic Impairment: A maximum daily dose of 20 mg of pantoprazole should not be exceeded. Renal Impairment and older adults generally require no dose adjustment. Pediatric dosing (age 5 and older) for some conditions is weight-based (e.g., 20 mg or 40 mg daily).

If a dose is missed, the standard procedure is to take the dose as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Recent Clinical Evidence

Evidence in Rheumatoid Arthritis (RA)

Research evaluated study objectives that focused on changes in participant pain levels associated with active Rheumatoid Arthritis (RA). Research also examined whether the compound was associated with changes in joint function and inflammation. Information on suitability for individual patients is not provided here.

Studies investigated the timeframe and persistence of symptom changes following administration. Observations suggested that, for some participants, changes were reported early in the study period.


Combination Therapy Trials

Studies explored the outcome of using the compound in combination with physical therapy. These trials typically measured changes in range of motion and overall disease activity scores compared to physical therapy alone. Study findings were mixed across the different populations evaluated.


Biological Activity and Trial Administration

Studies investigated the biological activity of the compound. The relevance of these findings in clinical practice has not been fully established.

Research included trials evaluating various administered amounts during the initial period. Studies on people with pre-existing heart conditions are limited. This group was typically excluded from the primary efficacy trials.


Long-Term Monitoring

The available evidence primarily comes from studies of up to 12 months in duration. Research monitored participants for changes in specific laboratory markers, adverse event incidence, and the need for adjustments to the administered amount.

Key Studies & References

  1. NICE Guideline NG100: Management of Rheumatoid Arthritis in Adults (Relevant to treatment protocols and evidence standards)

Frequently Asked Questions (FAQ)

Common questions about Perloc (FAQ)


Q: How quickly does Perloc start to work?

A: Perloc's full acid-blocking effect is not immediately noticeable and may require several days of consistent use to reach its maximum therapeutic benefit. Based on clinical studies, symptom improvement may begin within the first week of starting therapy.

Q: Is Perloc the same as [common similar drug name]?

A: The active ingredient in Perloc, pantoprazole, belongs to a class of medicines called Proton Pump Inhibitors (PPIs). While all PPIs share a similar function of reducing stomach acid, they are chemically distinct from one another, which means they can have different approved uses and unique interaction profiles.

Q: Does Perloc cause drowsiness or fatigue?

A: Official safety information for Perloc documents that dizziness is a common side effect, and fatigue, or unusual tiredness, is listed as an uncommon side effect. Because these effects are documented, individuals should be aware of these risks when driving or operating complex machinery.

Q: Can Perloc be taken long-term?

A: The initial treatment for most approved uses is short-term, typically up to eight weeks. Regulatory documents warn that using Perloc for a year or longer is associated with certain risks, including an increased risk of bone fracture, low magnesium levels, and Vitamin B-12 deficiency. Long-term use is associated with these risks and should only be undertaken after careful consideration by a healthcare professional.

Q: Is it important to take Perloc with food or on an empty stomach?

A: The timing depends on the formulation you are taking. Perloc delayed-release tablets can be taken with or without food. However, the delayed-release granules must be administered approximately 30 minutes before a meal for optimal efficacy, as directed by the product information.

Q: Can Perloc cause stomach upset or nausea?

A: Yes, official safety information indicates that adverse reactions affecting the stomach and digestive system are common. These include documented reactions such as nausea, vomiting, abdominal pain, and diarrhea.

Q: Does Perloc change the way other medicines are absorbed?

A: Yes, Perloc works by increasing the pH (making it less acidic) in your stomach. Because of this change, certain other medicines, particularly those that require an acidic environment to be absorbed properly, may not work as effectively when taken concurrently with Perloc.

Q: Is it normal if Perloc makes me feel a little dizzy?

A: Yes, official adverse reaction reports indicate that dizziness is a common side effect. If this symptom is disruptive or persists, patients are advised to consult with a healthcare professional, as is standard practice for side effects.

Q: Where can I find reliable information on Perloc clinical trials?

A: Authoritative information regarding Perloc's clinical trials, including study results and regulatory summaries, can be found on government websites. Reliable sources include the DailyMed product labeling and the National Institutes of Health (NIH) ClinicalTrials.gov registry.

Q: What's the main difference between Perloc and over-the-counter options?

A: Perloc is a prescription-only medication approved for specific conditions such as erosive esophagitis. In contrast, some other Proton Pump Inhibitors (PPIs) are available without a prescription for the short-term management of frequent heartburn.

Q: Is it safe to drink alcohol while using Perloc?

A: The official labeling does not address the use of alcohol with Perloc. However, alcohol consumption is generally known to irritate the stomach lining and stimulate acid production, which could potentially diminish the intended anti-secretory benefit of the medication.

Q: Can older adults safely use Perloc?

A: Studies in older adults generally showed similar effectiveness and side effect profiles compared to younger patients, and dose adjustment is usually not required based on age. However, regulatory warnings note that long-term use in older adults may carry an increased risk of bone fracture and Vitamin B-12 deficiency.

Q: Is Perloc suitable for use by children?

A: Official regulatory documents indicate Perloc is approved for the short-term treatment of specific conditions, like erosive esophagitis, in specific pediatric age groups. The safety and effectiveness of the medication have not been established for general use in children under the age of five.

Q: Is Perloc available without a prescription?

A: Currently, Perloc (pantoprazole delayed-release tablets) is a medication that requires a valid prescription for administration.

Q: Does Perloc have a risk of dependency or addiction?

A: Perloc is not classified as an addictive substance. However, abruptly discontinuing the medication after prolonged use may lead to a temporary increase in acid production, known as rebound acid hypersecretion, which can cause symptoms to return.

Q: What does the research say about the effectiveness of Perloc?

A: Clinical studies provided to regulatory authorities have demonstrated that Perloc is effective for its approved uses. Specifically, the research confirms its ability to promote healing and provide sustained symptom relief for conditions like erosive esophagitis when taken as recommended.

Q: Are there any studies comparing Perloc to placebos?

A: Yes, the effectiveness of Perloc for its approved indications was established through controlled, randomized clinical trials. These studies followed standard scientific practice and included comparison groups that received a placebo.

Q: Is it okay to take antacids or stomach relievers with Perloc?

A: Yes, official product information indicates that antacids or other stomach relievers can be taken concurrently with Perloc. Antacids do not appear to interfere with the absorption or effectiveness of Perloc.

Q: What are the guidelines for discontinuing Perloc?

A: For short-term treatment, stopping Perloc abruptly is generally acceptable. Regulatory information suggests that for patients on long-term therapy, a healthcare professional may advise a gradual reduction or transition to manage the potential for rebound symptoms upon discontinuation.

Q: Can Perloc be used during pregnancy?

A: Official labeling advises that use is only considered when the potential benefit is thought to outweigh the potential risks, consistent with the standard approach where adequate and well-controlled studies in pregnant women are not available.

Q: Is Perloc safe to take while breastfeeding?

A: Since Perloc is known to be excreted into human milk, the decision regarding its use while breastfeeding should be made by a healthcare professional, balancing the clinical needs of the mother against the potential for infant exposure.

Q: Does Perloc interact with any common anti-depressants?

A: Official documentation advises that Perloc can interact with certain anti-depressants. This is due to the fact that some anti-depressants require a specific stomach pH for proper absorption. Additionally, Perloc may affect the levels of some anti-depressants in the blood, necessitating careful monitoring by a healthcare professional.

Q: How long does Perloc take to fully clear out of the system?

A: The measured half-life of Perloc, which is the time it takes for the concentration of the drug in the body to reduce by half, is approximately one hour. However, its therapeutic effect on acid secretion lasts much longer because of the irreversible way it works at a cellular level.

Q: Is Perloc known to cause any skin reactions or rashes?

A: Yes, official safety information documents that rash and itching (pruritus) are uncommon side effects. In rare instances, more severe skin reactions known as Severe Cutaneous Adverse Reactions (SCAR) have also been reported.

Q: Does Perloc affect sleep patterns?

A: Official adverse reaction reports indicate that sleep disorders are an uncommon side effect documented in association with Perloc use.

How should Perloc be stored and disposed of?

How to Store and Dispose of Perloc (Pantoprazole Sodium)

The official labeling for Perloc (pantoprazole sodium delayed-release tablets) defines specific rules for storage, handling, and disposal.


Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), to preserve the integrity of the active substance. The medicine must be kept out of the sight and reach of children.

Condition Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Must be protected from moisture and direct light and kept from freezing
Container Store in the original container and keep tightly closed

Disposal

Unused or expired Perloc must be disposed of in accordance with local regulations and is generally prohibited from being put into wastewater or household trash. Patients should use a local drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perloc found in:

A-Z Index: